556813-39-9 Usage
Uses
Used in Pharmaceutical Industry:
CHIR 98014 is used as a research tool for studying the role of GSK-3 in various biological processes and diseases. It helps researchers understand the molecular mechanisms underlying the regulation of GSK-3 and its potential as a therapeutic target.
Used in Neurodegenerative Diseases:
CHIR 98014 is used as a potential therapeutic agent for the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has been shown to reduce tau phosphorylation, a key event in the pathogenesis of these diseases, and protect neurons from degeneration.
Used in Osteoporosis Treatment:
CHIR 98014 is used as a potential treatment for osteoporosis, a condition characterized by reduced bone density and increased risk of fractures. It has been shown to promote bone formation and inhibit bone resorption, thereby improving bone health.
Used in Bipolar Mood Disorder Treatment:
CHIR 98014 is used as a potential treatment for bipolar mood disorder, a mental health condition characterized by extreme mood swings. It has been shown to modulate the activity of GSK-3, which is implicated in the regulation of mood and has been suggested as a potential therapeutic target for bipolar disorder treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 556813-39-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,5,6,8,1 and 3 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 556813-39:
(8*5)+(7*5)+(6*6)+(5*8)+(4*1)+(3*3)+(2*3)+(1*9)=179
179 % 10 = 9
So 556813-39-9 is a valid CAS Registry Number.
InChI:InChI=1/C20H17Cl2N9O2/c21-11-1-2-12(14(22)9-11)17-13(19-25-6-7-26-19)10-28-20(30-17)27-8-5-24-16-4-3-15(31(32)33)18(23)29-16/h1-4,6-7,9-10H,5,8H2,(H,25,26)(H3,23,24,29)(H,27,28,30)
556813-39-9Relevant academic research and scientific papers
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3
Wagman, Allan S.,Boyce, Rustum S.,Brown, Sean P.,Fang, Eric,Goff, Dane,Jansen, Johanna M.,Le, Vincent P.,Levine, Barry H.,Ng, Simon C.,Ni, Zhi-Jie,Nuss, John M.,Pfister, Keith B.,Ramurthy, Savithri,Renhowe, Paul A.,Ring, David B.,Shu, Wei,Subramanian, Sharadha,Zhou, Xiaohui A.,Shafer, Cynthia M.,Harrison, Stephen D.,Johnson, Kirk W.,Bussiere, Dirksen E.
, p. 8482 - 8514 (2017/11/03)
In an effort to identify new antidiabetic agents, we have discovered a novel family of (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine analogues which are inhibitors of human glycogen synthase kinase 3 (GSK3). We developed efficient synthetic routes to explore a wide variety of substitution patterns and convergently access a diverse array of analogues. Compound 1 (CHIR-911, CT-99021, or CHIR-73911) emerged from an exploration of heterocycles at the C-5 position, phenyl groups at C-4, and a variety of differently substituted linker and aminopyridine moieties attached at the C-2 position. These compounds exhibited GSK3 IC50s in the low nanomolar range and excellent selectivity. They activate glycogen synthase in insulin receptor-expressing CHO-IR cells and primary rat hepatocytes. Evaluation of lead compounds 1 and 2 (CHIR-611 or CT-98014) in rodent models of type 2 diabetes revealed that single oral doses lowered hyperglycemia within 60 min, enhanced insulin-stimulated glucose transport, and improved glucose disposal without increasing insulin levels.
